Dr. Joaquin Mateo speaks to ecancer about the PROFound trial and the recent updates in treating prostate cancer presented at the virtual ESMO 2020.
Dr. Mateo, initially outlines the reasoning for using PARP inhibitors as a viable drug option for treating prostate cancer and then explains the screening process for choosing suitable patients to treat with olaparib at the PROFound trial.
He then, further, mentions the key outcomes observed in the group treated with olaparib and the group treated with standard hormone therapy in the PROFound trial.
Dr. Mateo goes into some detail regarding the molecular markers e.g. BRCA mutations that can open new avenues of treatment via synthetic lethality.
In the end Dr. Mateo highlights the clinical implications the results from the PROFound trial can have on the treatment of prostate cancer and other new updates regarding this treatment.
This programme has been supported by an unrestricted educational grant from Pfizer.